{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:02:49Z","timestamp":1749268969769,"version":"3.41.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-23205-1","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:19:40Z","timestamp":1749197980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory analysis of the economically justifiable price of reslizumab for asthma severe in Colombia"],"prefix":"10.1186","volume":"25","author":[{"given":"Jefferson Antonio","family":"Buend\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres Felipe","family":"Zuluaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"10258","key":"23205_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases","year":"2020","unstructured":"Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"6","key":"23205_CR2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2500\/aap.2015.36.3908","volume":"36","author":"DM Lang","year":"2015","unstructured":"Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36(6):418\u201324.","journal-title":"Allergy Asthma Proc"},{"key":"23205_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2466-12-17","volume":"12","author":"RJ Dennis","year":"2012","unstructured":"Dennis RJ, et al. Prevalence of asthma and other allergic conditions in Colombia 2009\u20132010: a cross-sectional study. BMC Pulm Med. 2012;12:17.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"23205_CR4","doi-asserted-by":"publisher","first-page":"e12232","DOI":"10.1002\/clt2.12232","volume":"13","author":"PJ Cooper","year":"2023","unstructured":"Cooper PJ, et al. Understanding and controlling asthma in Latin America: a review of recent research informed by the SCAALA programme. Clin Transl Allergy. 2023;13(3):e12232.","journal-title":"Clin Transl Allergy"},{"key":"23205_CR5","unstructured":"Administration FaD. FDA approves Cinqair to treat severe asthma. 2016; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-cinqair-treat-severe-asthma"},{"key":"23205_CR6","unstructured":"Agency EM. Cinqaero. 2016; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cinqaero"},{"issue":"7","key":"23205_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40265-017-0740-2","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED, Brusselle G. Reslizumab in eosinophilic asthma: a review. Drugs. 2017;77(7):777\u201384.","journal-title":"Drugs"},{"issue":"10","key":"23205_CR8","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","volume":"184","author":"M Castro","year":"2011","unstructured":"Castro M, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125\u201332.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"23205_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/heapol\/czw096","volume":"32","author":"LA Robinson","year":"2017","unstructured":"Robinson LA, et al. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141\u20135.","journal-title":"Health Policy Plan"},{"issue":"7197","key":"23205_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/bmj.318.7197.1551","volume":"318","author":"S Palmer","year":"1999","unstructured":"Palmer S, Raftery J. Economic notes: opportunity cost. BMJ. 1999;318(7197):1551\u20132.","journal-title":"BMJ"},{"issue":"6","key":"23205_CR11","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, et al. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force\u20133. Value Health. 2012;15(6):812\u201320.","journal-title":"Value Health"},{"issue":"5","key":"23205_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"23205_CR13","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1016\/j.jaip.2022.04.014","volume":"10","author":"S Hashimoto","year":"2022","unstructured":"Hashimoto S, et al. Real-world effectiveness of reslizumab in patients with severe eosinophilic asthma - first initiators and switchers. J Allergy Clin Immunol Pract. 2022;10(8):2099\u2013e21086.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"23205_CR14","doi-asserted-by":"crossref","unstructured":"Beltr\u00e1n J, Moraes GA, Alfonso Cristancho F, Di Boscio R, Soares V. C. Caracter\u00edsticas cl\u00ednicas, gravedad y control del asma en Colombia: un an\u00e1lisis post hoc del estudio ASLA (Asthma control in Latin America). rev. colomb. neumol 2020 [cited 2024 25\/02\/2024]; Available from: https:\/\/revistas.asoneumocito.org\/index.php\/rcneumologia\/article\/view\/405","DOI":"10.30789\/rcneumologia.v31.n2.2019.405"},{"key":"23205_CR15","doi-asserted-by":"crossref","unstructured":"Rosselli D, et al. Perfil cl\u00ednico y Costos Directos de La Atenci\u00f3n de Asma En Una red de instituciones de Salud En Bogot\u00e1. Revista Colombiana de Neumolog\u00eda; 2020. p. 31.","DOI":"10.30789\/rcneumologia.v31.n2.2019.420"},{"key":"23205_CR16","unstructured":"Excellence. N.I.f.H.a.C. Single technology appraisal. Reslizumab for treating eosinophilic asthma inadequately controlled on inhaled corticosteroids. 2017; Available from: www.nice.org.uk\/guidance\/ta479\/history"},{"issue":"7","key":"23205_CR17","first-page":"CD010834","volume":"7","author":"HA Farne","year":"2022","unstructured":"Farne HA, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"23205_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3111\/13696998.2015.1025793","volume":"18","author":"TR Einarson","year":"2015","unstructured":"Einarson TR, et al. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550\u201363.","journal-title":"J Med Econ"},{"issue":"1","key":"23205_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3\u20139.","journal-title":"Value Health"},{"key":"23205_CR20","unstructured":"Salud I. d.E.T.e. Manual metodol\u00f3gico para la elaboraci\u00f3n de evaluaciones de efectividad, seguridad y validez diagn\u00f3stica de tecnolog\u00edas en salud. 2014 06\/05\/2021]; Available from: https:\/\/www.minsalud.gov.co\/sites\/rid\/Lists\/BibliotecaDigital\/RIDE\/INEC\/IETS\/manual-metodologico-elaboracion-de-evaluaciones-de-efectividad.pdf"},{"key":"23205_CR21","doi-asserted-by":"crossref","unstructured":"Fernandez-Trujillo L, et al. Caracterizaci\u00f3n de Los Pacientes Con Asma Severa admitidos a Una Unidad de Cuidado intensivo. Estudio descriptivo En Un hospital de referencia. Revista Colombiana de Neumolog\u00eda; 2016. p. 27.","DOI":"10.30789\/rcneumologia.v27.n2.2015.25"},{"issue":"1","key":"23205_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/13696998.2022.2074195","volume":"25","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. J Med Econ. 2022;25(1):679\u201390.","journal-title":"J Med Econ"},{"issue":"Suppl 1","key":"23205_CR23","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/infdis\/jiab118","volume":"226","author":"F Zeevat","year":"2022","unstructured":"Zeevat F, et al. Exploratory analysis of the economically justifiable price of a hypothetical RSV vaccine for older adults in the Netherlands and the United Kingdom. J Infect Dis. 2022;226(Suppl 1):S102\u20139.","journal-title":"J Infect Dis"},{"key":"23205_CR24","doi-asserted-by":"crossref","unstructured":"Buendia JA, Acuna-Cordero R, Rodriguez-Martinez CE. Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia. Pediatr Pulmonol; 2024.","DOI":"10.22541\/au.169642813.35920101\/v1"},{"issue":"6","key":"23205_CR25","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342.","journal-title":"Lancet Glob Health"},{"key":"23205_CR26","doi-asserted-by":"crossref","unstructured":"Espinosa O, et al. Estimating Cost-Effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan; 2021.","DOI":"10.1093\/heapol\/czab146"},{"key":"23205_CR27","unstructured":"Departamento N, DANE). and D.E. (. Archivo Nacional de Datos. 2019 [cited 03\/04\/2020 03\/04\/2020]; Available from: https:\/\/sitios.dane.gov.co\/anda-index\/"},{"key":"23205_CR28","unstructured":"Garc\u00eda Calder\u00f3n CP. B.M. Eosin\u00f3filos en sangre y en esputo como predictores de severidad en crisis asm\u00e1tica. 2010; Available from: https:\/\/revistas.asoneumocito.org\/index.php\/rcneumologia\/article\/view\/679"},{"key":"23205_CR29","unstructured":"Neffen H et al. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. (1020\u20134989 (Print))."},{"issue":"9","key":"23205_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/03007995.2019.1605159","volume":"35","author":"S Han","year":"2019","unstructured":"Han S, et al. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting beta(2)-agonists in South Korea. Curr Med Res Opin. 2019;35(9):1597\u2013605.","journal-title":"Curr Med Res Opin"},{"key":"23205_CR31","unstructured":"Health. C.A.f.D.a.T.i. Reslizumab. Common Drug Review. Clinical Pharmacoeconomic Report. 2017; Available from: www.cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0495_Cinqair_PE_Report.pdf"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23205-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-23205-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-23205-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:19:48Z","timestamp":1749197988000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-23205-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23205"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-23205-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of University of Antioquia. The need for consent was waived by an IRB (2015\u20134690), following local regulations of resolution 8430\/93, because this is a study which all information was extracted from the literature and do not use data from patients\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2116"}}